GHO Capital, a private equity firm, completed an investment in RoslinCT, a CDMO firm. Financial terms were not disclosed. “RoslinCT is renowned for its best-in-class services in developing and manufacturing advanced cell therapies and we are delighted to partner with the team. With an established background in regenerative medicines and a strong foothold in Scotland as the leading centre for cell therapy research, RoslinCT, with our investment and specialist expertise, is uniquely positioned to drive the next stage of its growth. We look forward to realising the shared ambition for RoslinCT become a global CDMO with commercialised cell therapy manufacturing capabilities," GHO Capital.